Abstract:Multiple sclerosis [MS] is a progressive autoimmune condition that primarily affects young people and is characterized by demyelination and neurodegeneration of the central nervous system [CNS]. This in-depth review explores the complex involvement of oligodendrocytes, the primary myelin- producing cells in the CNS, in the pathophysiology of MS. It discusses the biochemical processes and signalling pathways required for oligodendrocytes to function and remain alive, as well as how they might fail and cause demyelination to occur. We investigate developing therapeutic options that target remyelination, a fundamental component of MS treatment. Remyelination approaches promote the survival and differentiation of oligodendrocyte precursor cells [OPCs], restoring myelin sheaths. This improves nerve fibre function and may prevent MS from worsening. We examine crucial parameters influencing remyelination success, such as OPC density, ageing, and signalling pathway regulation [e.g., Retinoid X receptor, LINGO-1, Notch]. The review also examines existing neuroprotective and antiinflammatory medications being studied to see if they can assist oligodendrocytes in surviving and reducing the severity of MS symptoms. The review focuses on medicines that target the myelin metabolism in oligodendrocytes. Altering oligodendrocyte metabolism has been linked to reversing demyelination and improving MS patient outcomes through various mechanisms. We also explore potential breakthroughs, including innovative antisense technologies, deep brain stimulation, and the impact of gut health and exercise on MS development. The article discusses the possibility of personalized medicine in MS therapy, emphasizing the importance of specific medicines based on individual molecular profiles. The study emphasizes the need for reliable biomarkers and improved imaging tools for monitoring disease progression and therapy response. Finally, this review focuses on the importance of oligodendrocytes in MS and the potential for remyelination therapy. It also underlines the importance of continued research to develop more effective treatment regimens, taking into account the complexities of MS pathology and the different factors that influence disease progression and treatment.

Mechanisms of Demyelination and Remyelination Strategies for Multiple Sclerosis

[Mechanisms Underlying Remyelination with Special Focus on Demyelination Models of Multiple Sclerosis].

Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches

Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials

Remyelinating Pharmacotherapies in Multiple Sclerosis

Targeting Oligodendrocyte Dynamics and Remyelination: Emerging Therapies and Personalized Approaches in Multiple Sclerosis Management

Emerging myelin repair agents in preclinical and early clinical development for the treatment of multiple sclerosis

Cell-based remyelinating therapy in inflammatory demyelinating injury of the CNS

Immune System Dysregulation in the Progression of Multiple Sclerosis: Molecular Insights and Therapeutic Implications

Cell‐based experimental strategies for myelin repair in multiple sclerosis

Remyelination in the CNS: from biology to therapy

Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis

Remyelinating Drugs at a Crossroad: How to Improve Clinical Efficacy and Drug Screenings

New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis

Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis

The Study of Remyelinating Therapies in Multiple Sclerosis: Visual Outcomes as a Window Into Repair

CXCL12/CXCR4/CXCR7 Chemokine Axis in the Central Nervous System: Therapeutic Targets for Remyelination in Demyelinating Diseases

Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action

The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cells

Restoring immune suppression in the multiple sclerosis brain

Wnt Signaling in Remyelination in Multiple Sclerosis: Friend or Foe?